CANADIAN CANCER TRIALS GROUP – GI DISEASE SITE COMMITTEE

RECTAL
DISEASE ORIENTED GROUP

AGENDA
OPEN SESSION

VENUE: ROSSETTI ROOM, CHELSEA HOTEL, TORONTO

DATE: SATURDAY, APRIL 29th, 2017

TIME: 09:00 – 10:00

CHAIRS: DR. HAGEN KENNECKE & DR. REBECCA AUER

09:00 WELCOME AND INTRODUCTION  DR. H. KENNECKE / DR. R. AUER

09:00 ACTIVE/RECENTLY CLOSED TRIALS FOR UPDATE
CRC.7 (NCCTG N1048- PROSPECT): A PHASE II/III TRIAL OF NEOADJUVANT FOLFOX, WITH SELECTIVE USE OF COMBINED MODALITY CHEMORADIATION VERSUS PREOPERATIVE COMBINED MODALITY CHEMORADIATION FOR LOCALLY ADVANCED RECTAL CANCER PATIENTS UNDERGOING LOW ANTERIOR RESECTION WITH TOTAL MESORECTAL EXCISION  DR. H. KENNECKE

IND 228: A PHASE II STUDY OF DURVALUMAB AND TREMELIMUMAB IN PATIENTS WITH ADVANCED RARE TUMOURS (ANAL CANCER COHORT)  DR. R. AUER

09:10 APPROVED TRIALS IN DEVELOPMENT
CO.28: NEOADJUVANT CHEMOTHERAPY, EXCISION AND OBSERVATION FOR EARLY RECTAL CANCER: THE NEO TRIAL  DR. C. BROWN / DR. H. KENNECKE

09:25 NEW CONCEPTS IN DEVELOPMENT
SPAR STUDY (AGITG): A RANDOMISED, PLACEBO-CONTROLLED PHASE II TRIAL OF SIMVASTATIN IN ADDITION TO STANDARD CHEMOTHERAPY AND RADIATION IN PREOPERATIVE TREATMENT FOR RECTAL CANCER  DR. H. KENNECKE

09:40 INTERGROUP TASK FORCE UPDATE
TNT (NRG GI-002): A PHASE II CLINICAL TRIAL PLATFORM OF SENSITIZATION UTILIZING TOTAL NEOADJUVANT THERAPY (TNT) IN RECTAL CANCER  DR. H. KENNECKE

EA2165: A RANDOMIZED PHASE II PLACEBO CONTROLLED STUDY OF NIVOLUMAB AFTER COMBINED MODALITY THERAPY (CMT) IN HIGH RISK ANAL CANCER  DR. R. AUER

10:00 CLOSING REMARKS